Ua hoʻolaha ʻo Dianthus Therapeutics i kēia lā i ka hoʻopau ʻana o kāna kālā $ 100 miliona Series A i alakaʻi ʻia e 5AM Ventures, Avidity Partners, a me Fidelity Management & Research Company, me ke komo ʻana mai nā mea hoʻopukapuka hou e like me Wedbush Healthcare Partners a me nā mea hoʻopukapuka hoʻokumu ʻo Fairmount, Tellus BioVentures, a me Venrock Healthcare Capital Partners . E hoʻohana ʻia ke kālā no ka hoʻonui ʻana i nā hui alakaʻi a me nā hui ʻepekema, e hoʻonui i ka papahana alakaʻi o ka hui, DNTH103, i ke keʻena hauʻoli i kēia makahiki, a e hoʻolalelale i nā papahana pipeline hou aʻe no ka poʻe e noho nei me nā maʻi autoimmune koʻikoʻi. ʻO ka DNTH103 he antibody monoclonal ikaika a hiki i ka hanauna e koho ana i ke ʻano ikaika o ka hoʻopiha ʻana i nā C1s, hiki ke hiki ke hoʻohaʻahaʻa i ka nui dosing a me ka hoʻokele subcutaneous liʻiliʻi i hoʻonui ʻia me ka ʻenehana hoʻonui hapalua ola.
Ua hoʻolaha pū ʻo Dianthus i ke koho ʻana iā Marino Garcia i Pelekikena a me Luna Nui, e hui pū ana i Nowemapa 2021, a me Simrat Randhawa, MD, MBA, ma ke ʻano he Luna Lapaʻau Nui. ʻO Mr. Garcia, he mea hana ʻoihana kahiko a me ka mea hoʻolālā, lawe mai i ʻoi aku ma mua o 25 mau makahiki o ka ʻike ʻoihana i ka hoʻomohala ʻana i ka ʻoihana a me nā kuleana alakaʻi ʻoihana ma nā hui biotech a me ka lāʻau lapaʻau, ʻo ia hoʻi ma ke ʻano he Hope Pelekikena Nui, ʻOihana a me ka Hoʻomohala ʻoihana ma Zealand Pharma. Lawe ʻo Kauka Randhawa i nā makahiki he 20 o ka hoʻomaʻamaʻa lapaʻau a me ka ʻike ʻoihana lāʻau lapaʻau iā Dianthus, me nā kuleana alakaʻi kiʻekiʻe i kālele ʻia i nā wahi maʻi autoimmune a me nā maʻi laha. Ua lawelawe hou ʻo ia ma ke ʻano he Hope Pelekikena Nui o ka Clinical and Medical Affairs ma Aurinia Pharmaceuticals.
"Ke kūpaʻa nei mākou i ka hoʻomaikaʻi ʻana i ke ola o ka poʻe e noho nei me nā maʻi autoimmune koʻikoʻi a ʻikeʻole ʻia e hiki i kā mākou antibodies koho ke hiki ke lilo i mea lapaʻau maikaʻi loa," wahi a Marino Garcia, Pelekikena a me Luna Nui, Dianthus Therapeutics. "Pono mākou i ka loaʻa ʻana o kahi hui ikaika o nā mea hoʻopukapuka biotech alakaʻi, nā lālā ʻike o ka Papa, a me nā alakaʻi a me nā ʻepekema i ko mākou hoʻomaka ʻana i kā mākou moho alakaʻi i ke keʻena ma hope o kēia makahiki, e hoʻomohala hou i kā mākou pipeline ʻike, a hoʻonui i kā mākou hui i nā mahina e hiki mai ana. . Ua hoʻonohonoho ʻia ʻo Dianthus e lilo i alakaʻi alakaʻi a me ka hanauna hou e alakaʻi ʻia e ka ʻike hohonu o nā pono o nā maʻi.
Hoʻohana ʻo Dianthus i ka mana o ke koho i nā ala hoʻohui e hana i nā antibodies monoclonal ikaika me ka hiki ke lanakila i nā palena o nā lāʻau lapaʻau hoʻohui i kēia manawa. ʻAʻole like me nā lāʻau lapaʻau antibody o kēia manawa e hoʻopaʻa ʻia i nā protein hoʻohui ʻole a me ka ikaika, koho ʻo DNTH103 i ke ʻano hana o ka C1s complement protein, e hiki ai ke hoʻohaʻahaʻa i ka nui o ka dosing a me ka liʻiliʻi o ka lawelawe ʻana. ʻO kāna ʻenehana hoʻonui hapalua ola e hōʻemi hou i ka pinepine dosing. Me kēia mau ʻano ʻokoʻa a me ka inhibition kiʻekiʻe o ka C1s, ua hoʻolālā ʻia ʻo DNTH103 e hoʻomaha i ke kaumaha o ka nui o ka nui, ka hoʻokele pinepine ʻana me nā infusions IV a i ʻole nā mea kūpono ʻole, pinepine subcutaneous dosing. ʻO ka hoʻonui ʻana i ka hoʻomohala ʻana i kahi lāʻau subcutaneous maʻalahi hiki ke hoʻololi i ka hoʻonui ʻana i ka nui o nā poʻe maʻi e hiki ke pōmaikaʻi mai ka hoʻokō ʻana i nā lāʻau lapaʻau, ʻoiai e hōʻemi ana i ka ʻehaʻeha a me nā pilikia e hoʻopuni ana i ke ola o nā poʻe maʻi i kēia lā - i ka hopena e ʻae i nā poʻe maʻi hou e ola i nā ola olakino i ko lākou piha. hiki.
"Haʻaheo mākou e kākoʻo iā Dianthus Therapeutics i ka holomua ʻana i ka ʻike ʻana a me ka hoʻomohala ʻana o ka hanauna hou, potent, a me ka ʻokoʻa loa o ka antibody complement therapeutics," wahi a Paula Soteropoulos, Luna Hoʻokele o Dianthus a me Strategic Advisor i 5AM Ventures. "Me ke alakaʻi ʻana o ka Pelekikena a me Luna Nui ʻo Marino Garcia, a me kahi pūʻulu akamai o nā alakaʻi biotech a me nā ʻoihana e paʻa i kahi moʻolelo o ka kūleʻa, ke kakali nei mākou i ka ʻike ʻana iā Dianthus e lawe mai i kā lākou mau lāʻau lapaʻau hou i nā poʻe maʻi e noho ana me ka maʻi paʻakikī. nā maʻi autoimmune.
He aha e lawe ʻia mai kēia ʻatikala:
- “With the leadership of the recently appointed President and CEO Marino Garcia, and a talented team of seasoned biotech executives and entrepreneurs who hold an extensive track record of success, we look forward to seeing Dianthus bring their novel therapies to patients living with severe and rare autoimmune diseases.
- Accelerating the development of a more convenient subcutaneous therapy could be transformative in expanding the potential patient populations that could benefit from complement therapies, while reducing the discomfort and disruptions that pervade the lives of patients today – ultimately allowing more patients to live healthier lives to their fullest potential.
- “We are privileged to have a strong syndicate of leading biotech investors, experienced Board members, and accomplished leaders and scientists as we advance our lead candidate into the clinic later this year, further develop our discovery pipeline, and expand our team in the coming months.
